Invention Application
US20160312207A1 R-SPONDIN ANTAGONISTS AND METHODS OF TREATING CANCER ASSOCIATED WITH ABERRANT ACTIVATION OF WNT SIGNALING
审中-公开
R-SPONDIN拮抗剂和治疗与WNT信号的激活相关的癌症的方法
- Patent Title: R-SPONDIN ANTAGONISTS AND METHODS OF TREATING CANCER ASSOCIATED WITH ABERRANT ACTIVATION OF WNT SIGNALING
- Patent Title (中): R-SPONDIN拮抗剂和治疗与WNT信号的激活相关的癌症的方法
-
Application No.: US15134353Application Date: 2016-04-20
-
Publication No.: US20160312207A1Publication Date: 2016-10-27
- Inventor: Calvin J. Kuo , Kelley Yan , Junlei Chang
- Applicant: The Board of Trustees of the Leland Stanford Junior University
- Main IPC: C12N9/00
- IPC: C12N9/00 ; A61K9/00 ; A61K38/53 ; C12N7/00
Abstract:
Compositions and methods for treating cancer associated with aberrant activation of the Wnt signaling pathway are disclosed. In particular, the invention relates to R-spondin antagonists comprising a soluble extracellular domain of ring finger 43 (RNF43) or E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and methods of treating cancer with such antagonists.
Information query
